Genelux executive reports sales of 3,219 and 973 shares

Genelux Corporation senior vice president of clinical development reported two sales of company common stock.

Rhea-AI Filing Summary

Genelux Corporation senior vice president of clinical development reported two sales of company common stock. On August 21, 2025, the reporting person sold 3,219 shares at $3.3574 per share, and on November 17, 2025, an additional 973 shares were sold at $5.3694 per share.

According to the disclosure, these shares were sold to cover estimated taxes related to the vesting of restricted stock units. After the reported transactions, the officer beneficially owned 145,844 shares of Genelux common stock directly.

Insider Trade Summary

Net Seller: 4,192 shares

Net Sell 2 txns

Insider Yu Yong

Role SVP, Clinical Development

Sold 4,192 shs ($16K)

Type	Security	Shares	Price	Value
Sale	Common Stock	973	$5.3694	$5K
Sale	Common Stock	3,219	$3.3574	$11K

Holdings After Transaction: Common Stock — 145,844 shares (Direct)

Footnotes (2)

1. F1. Represents shares sold by the Reporting Person to cover estimated taxes to be paid by the Reporting Person in connection with the vesting of restricted stock units.
2. F2. The total shown in Column 5 takes into account the transactions reported on Form 4 filed on August 29, 2025.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Who is the reporting person in the Genelux (GNLX) Form 4 filing?

The reporting person is an officer of Genelux Corporation, serving as SVP, Clinical Development.

What insider stock sales did Genelux (GNLX) disclose in this Form 4?

The filing shows that on August 21, 2025, the officer sold 3,219 shares of Genelux common stock at $3.3574 per share, and on November 17, 2025, sold an additional 973 shares at $5.3694 per share.

Why were shares of Genelux (GNLX) sold by the reporting person?

The explanation states that the reported shares were sold to cover estimated taxes payable by the reporting person in connection with the vesting of restricted stock units.

How many Genelux (GNLX) shares does the insider own after these transactions?

Following the reported transactions, the officer beneficially owned 145,844 shares of Genelux common stock, held directly.

Is the Genelux (GNLX) Form 4 filed by one or multiple reporting persons?

The document indicates that the Form 4 is filed by one reporting person, not by a group.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 12/11/2025 - 08:50 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Yu Yong

(Last) (First) (Middle)

C/O GENELUX CORPORATION

2625 TOWNSGATE ROAD, SUITE 230

(Street)

WESTLAKE VILLAGE CA 91361

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
GENELUX Corp [ GNLX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Clinical Development

3. Date of Earliest Transaction (Month/Day/Year)
08/21/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/21/2025		S(1)		3,219	D	$3.3574	146,817(2)	D
Common Stock	11/17/2025		S(1)		973	D	$5.3694	145,844(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares sold by the Reporting Person to cover estimated taxes to be paid by the Reporting Person in connection with the vesting of restricted stock units.

2. The total shown in Column 5 takes into account the transactions reported on Form 4 filed on August 29, 2025.

	/s/ Thomas Zindrick, J.D. Attorney-in-Fact	12/11/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.